Who decides in the EU?
Out of five Croatians in Brussels, roughly one in five Croatians decided who would speak for the other four in…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
Live Last read · last published · next check
Latest posts
Beyond the transplant list: the pediatric cardiomyopathy pipeline finally has momentum
Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy in children and the leading reason kids end up on…
Germany goes to Bangalore: Formycon’s India deal is the latest sign that biosimilar manufacturing is moving east — permanently
A Munich-based biosimilar developer just signed a strategic manufacturing partnership with an Indian CDMO. According to industry analysts, it is not the first such deal, and it will not be the last. The question is what Europe gets — and what it gives up — as the shift accelerates?
How the Hormuz blockade became a prolonged war: pharma’s supply nightmare deepens as truce fails and strait closes again
The 21-mile-wide waterway that supplies Europe's medicine cabinet is not reopening — it is effectively closed once more, live maritime tracking data and intelligence reports show. The crisis that began in February has evolved into an active theatre of war with no clear end in sight.
Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30
Poolbeg Pharma (AIM: POLB) said on 13 July that the first patient has been dosed in its POLB 001 TOPICAL trial, according to the company's RNS statement, and that University College London Hospital has now also been activated as a clinical trial site, with additional sites expected to open imminently. Investor reaction will hinge less on the milestone itself — dosing a first patient is table…
Four threats, one broken system: Moody’s onto something
A new white paper from one of the world's most influential credit agencies maps the forces tearing apart pharmaceutical supply chains. The diagnosis is accurate.
The Rerouting of Europe‘s medicine cabinet: How the Iran war is reshaping pharmaceutical supply chains
By Pharmaceutical Daily Editorial Staff As the conflict in the Middle East enters its second month, the pharmaceutical industry across…
Pharmakon bets again, this time the odds are harder to read
BioPharma Credit deploys another $125 million into a pre-approval biotech. But the company it just backed is the one whose stock fell more than 50% on its Phase 3 data.